Methods Treatment consisted of 2 days of outpatient conditioning chemotherapy (cyclophosphamide 300 mg/m 2 and fludarabine 25 mg/m 2 ), followed by two 29-day cycles of 3 once–weekly doses of 300 million FT500 cells/dose with subcutaneous IL-2 (6 MIU), and nivolumab, pembrolizumab, or atezolizumab administered at standard dose and schedule. Ethics Approval This study is being conducted in accordance with the Declaration of Helsinki and was approved by all Institutional Review Boards from each clinical site participating in the study. Specific approval numbers can be provided upon request.

2 years ago

Clinical • P1 data • Checkpoint inhibition

IL2 (Interleukin 2)

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • FT500

2years

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=37, Active, not recruiting, Fate Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Nov 2022 | Trial primary completion date: Mar 2022 --> Oct 2022

2 years ago

Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases

IL2 (Interleukin 2)

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • FT500

3years

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=37, Recruiting, Fate Therapeutics | N=76 --> 37 | Trial completion date: Jun 2022 --> Jul 2023

3 years ago

Clinical • Enrollment change • Trial completion date • Combination therapy • Checkpoint inhibition

IL2 (Interleukin 2)

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • FT500